CY1105795T1 - Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακων - Google Patents

Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακων

Info

Publication number
CY1105795T1
CY1105795T1 CY20061101680T CY061101680T CY1105795T1 CY 1105795 T1 CY1105795 T1 CY 1105795T1 CY 20061101680 T CY20061101680 T CY 20061101680T CY 061101680 T CY061101680 T CY 061101680T CY 1105795 T1 CY1105795 T1 CY 1105795T1
Authority
CY
Cyprus
Prior art keywords
orally administered
bioavailability
formulations
improving
administered drugs
Prior art date
Application number
CY20061101680T
Other languages
English (en)
Inventor
Johannes Henricus Matthias Schellens
Alfred Hermanus Schinkel
Original Assignee
Cancer Research Ventures Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Ventures Limited filed Critical Cancer Research Ventures Limited
Publication of CY1105795T1 publication Critical patent/CY1105795T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Μια μέθοδος αύξησης της συστηματικής έκθεσης κυττάρων που επιλέγονται από καρκινικά κύτταρα και φυσιολογικά κύτταρα σε μια χορηγούμενη από το στόμα φαρμακευτικώς δραστική ένωση, όπου ένας βιοενισχυτής που περιέχει έναν αναστολέα της προκαλούμενης από και/ή σχετιζόμενης με BCRP μεταφοράς φαρμάκων χορηγείται από το στόμα συγχρόνως με την αναφερόμενη χορηγούμενη από το στόμα φαρμακευτικώς δραστική ένωση, και στην οποία μέθοδο ο αναστολέας χορηγείται συγχρόνως με την φαρμακευτική ένωση.
CY20061101680T 1999-05-17 2006-11-16 Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακων CY1105795T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL1012066 1999-05-17
NL1012481 1999-06-30
PCT/NL2000/000331 WO2000069390A2 (en) 1999-05-17 2000-05-17 Compositions for improving bioavailability of orally administered drugs

Publications (1)

Publication Number Publication Date
CY1105795T1 true CY1105795T1 (el) 2011-02-02

Family

ID=26642978

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101680T CY1105795T1 (el) 1999-05-17 2006-11-16 Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακων

Country Status (10)

Country Link
US (2) US7030132B2 (el)
EP (2) EP1749540B1 (el)
AT (2) ATE337016T1 (el)
AU (1) AU4955200A (el)
CY (1) CY1105795T1 (el)
DE (2) DE60045114D1 (el)
DK (1) DK1189637T3 (el)
ES (1) ES2270834T3 (el)
PT (1) PT1189637E (el)
WO (1) WO2000069390A2 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DK1189637T3 (da) * 1999-05-17 2006-12-11 Cancer Res Ventures Ltd Produkter til forbedring af biotilgængeligheden for oralt indgivne medikamenter
HU0100947D0 (en) * 2001-03-02 2001-05-28 Solvo Kft Screening system based on expression of abcg2 half transporter protein in an expression system free of other abc-transporters, abcg2 homodimers
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers
US20080312250A1 (en) * 2004-07-01 2008-12-18 The Netherlands Cancer Institute Combination Comprising a Bcrp Inhibitor and 4- (4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl] -Benzamide
CN101010114B (zh) 2004-08-27 2010-05-26 皇家飞利浦电子股份有限公司 电子遥控药丸和用于供应至少一种药物的系统
WO2006056944A1 (en) * 2004-11-29 2006-06-01 Koninklijke Philips Electronics N.V. Electronically controlled pill
WO2006065125A1 (en) * 2004-12-16 2006-06-22 Het Nederlands Kanter Instituut Means and methods for determining and/or influencing transportation
WO2009083042A1 (en) * 2007-12-31 2009-07-09 Olaf Van Tellingen Methods and means for the treatment of cancer
US20100331827A1 (en) * 2008-02-18 2010-12-30 Koninklijke Philips Electronics N.V. Administration of drugs to a patient
CN101983029B (zh) * 2008-03-31 2015-01-14 皇家飞利浦电子股份有限公司 制备包括传感器的可吞服胶囊的方法
KR101367219B1 (ko) 2008-04-30 2014-03-14 지멘스 메디컬 솔루션즈 유에스에이, 인크. 기질 기재 ｐｅｔ 조영제
JP5500600B2 (ja) * 2008-06-19 2014-05-21 コーニンクレッカ フィリップス エヌ ヴェ 湿った環境における粉状薬物の供給のためのデバイス
RU2011102576A (ru) * 2008-06-25 2012-07-27 Конинклейке Филипс Электроникс Н.В. (Nl) Электронная таблетка, содержащая множество емкостей с лекарственным средствами
US10046109B2 (en) 2009-08-12 2018-08-14 Progenity, Inc. Drug delivery device with compressible drug reservoir
CN106432490B (zh) * 2016-09-14 2020-01-07 北京大学 一种abcg2单克隆抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201084A (en) 1982-06-25 1985-10-11 New Zealand Dev Finance 4-carboxamidoacridine derivatives and pharmaceutical compositions containing such
KR100220538B1 (ko) * 1991-01-11 1999-09-15 뮈쉘 쥐르밀 아크리딘 유도체
WO1994001408A1 (en) 1992-07-10 1994-01-20 Laboratoires Glaxo S.A. Anilide derivatives
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5786344A (en) 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
NZ295546A (en) 1994-10-05 1999-01-28 Glaxo Wellcome Inc Parenteral medicament containing n-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}- 9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide, surfactant, and buffer
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
GB9710612D0 (en) 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
DE69832173T2 (de) 1997-05-27 2006-08-03 IVAX RESEARCH, INC., Miami Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung
GB9718903D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1999040110A1 (en) * 1998-02-05 1999-08-12 University Of Maryland, Baltimore Breast cancer resistance protein (bcrp) and the dna which encodes it
JP2002518332A (ja) 1998-06-18 2002-06-25 ジョージワシントン大学 副作用低減を伴う癌治療のためのカンプトテシン化合物の投与方法
JP2002522392A (ja) 1998-08-05 2002-07-23 アベンテイス・フアルマ・ソシエテ・アノニム 低下された消化管毒性を有するカンプトテシン誘導体の使用
DK1189637T3 (da) * 1999-05-17 2006-12-11 Cancer Res Ventures Ltd Produkter til forbedring af biotilgængeligheden for oralt indgivne medikamenter
US6521635B1 (en) 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives

Also Published As

Publication number Publication date
ATE484295T1 (de) 2010-10-15
AU4955200A (en) 2000-12-05
WO2000069390A2 (en) 2000-11-23
US20020128282A1 (en) 2002-09-12
EP1749540A3 (en) 2007-05-30
US7030132B2 (en) 2006-04-18
DE60030283T2 (de) 2007-09-20
WO2000069390A3 (en) 2001-12-13
ATE337016T1 (de) 2006-09-15
ES2270834T3 (es) 2007-04-16
EP1749540A2 (en) 2007-02-07
EP1749540B1 (en) 2010-10-13
EP1189637A2 (en) 2002-03-27
DE60045114D1 (de) 2010-11-25
DK1189637T3 (da) 2006-12-11
US20060128743A1 (en) 2006-06-15
EP1189637B1 (en) 2006-08-23
PT1189637E (pt) 2007-01-31
DE60030283D1 (de) 2006-10-05

Similar Documents

Publication Publication Date Title
CY1105795T1 (el) Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακων
CY1118873T1 (el) Φαρμακευτικη δοσολογικη μορφη μιας φαρμακευτικα αποδεκτης ενωσης διαλυτοποιησης
CY1106727T1 (el) Ινδανυλ παραγωγα για την αντιμετωπιση ασθενειων αεραγωγων
CY1106072T1 (el) Φαρμακευτικη μορφη δοσης παρατεταμενης αποδεσμευσης απο του στοματος
TR200102226T2 (tr) Formoterol ve bir tiotropium tuzunun kombinasyonları
CY1112562T1 (el) Φαρμακευτικες συνθεσεις για τη στοματικη χορηγηση της καλσιτονινης
SE0003449D0 (sv) Anticancer compositions
AR023972A1 (es) Composiciones de medicamentos a base de compuestos anticolinergicamente activos y beta-mimeticos
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
NZ324801A (en) Oral pharmaceutical dosage form containing taxol or etoposide derivatives and a bioenhancer compound
DE60325354D1 (de) Topisch anwendbare pharmazeutische zubereitung
ATE356612T1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
DE60137960D1 (de) Pharmazeutische zusammensetzungen mit corticosteroiden und antiinfektiva
TR199900336T2 (xx) EAA antagonistleri olarak tetrahidrokinolin t�revleri.
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
DE60019334D1 (de) Antivirale arznei
DK1150704T3 (da) Melagatran til behandling af betændelse
WO2003020214A3 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
EA200701409A1 (ru) Новая композиция
DK1152763T3 (da) Anvendelse af desozypeganin til behandling af stofafhængighed
EA200602199A1 (ru) Композиции, содержащие глюкозаминогликан и нестероидное противовоспалительное средство
SE9902742D0 (sv) New pharmaceutical formultion
ITMI992736A0 (it) Composizioni farmaceutiche per la somministrazione localizzata nel cav o orale di farmaci antiinfiammatori non stereoidei utili per la terapi